Tamsulosin and cataract surgery complications

Article

According to a report in the Journal of the American Medical Association patients taking tamsulosin for benign prostrate enlargement within 14 days of cataract surgery may have an increased risk of complications.

According to a report in the Journal of the American Medical Association patients taking tamsulosin for benign prostrate enlargement within 14 days of cataract surgery may have an increased risk of complications.

Other similar medications do not increase the risk of these complications — which include lens loss, retinal detachment, and inflammation — according to Dr Chaim M. Bell, from St. Michael's Hospital, Toronto, and colleagues.

The findings hail from a study of 96,128 men, 66 years or older, who underwent cataract surgery in Ontario, Canada from 2002 to 2007. Of these patients, 3550 had taken tamsulosin within 14 days of surgery and 7426 had recent taken other so-called alpha-blocking agents.

Overall, 284 patients experienced an adverse event related to cataract surgery, and 280 of them were matched by age, surgeon, and year of surgery to 1102 patients who did not experience complications.

The report shows that the patients with complications were 2.3 times more likely to have recently taken tamsulosin than the comparison group. By contrast, no significant differences were noted in recent or prior exposure to other alpha-blockers.

The researchers calculate that for every 255 cataract surgery patients who have recently taken tamsulosin, one will develop a serious postop complication.

"Because the combination of cataract surgery and tamsulosin exposure is relatively common, patients should be properly appraised of the risks of drug therapy, and preoperative systems should focus on the identification of tamsulosin use by patients," the authors concluded.

SOURCE: Journal of the American Medical Association.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.